{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Day 8 of Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"55.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Day 1 of Cycle 2"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there were only two participants. Individual values reported: 32.4 µg/mL, 41.3 µg/mL","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Day 1 of Cycle 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Cmin was the concentration of study drug in the blood immediately before the next dose was administered. It was measured pre-dose at all visits and was summarized using descriptive statistics.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Ramucirumab + Gemcitabine + Docetaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Prior to ramucirumab infusion on Day 8 of Cycle 1, Day 1 of Cycle 2 and Day 1 of Cycle 5","title":"PK: Minimum Serum Concentration of Ramucirumab (Cmin)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}